Abstract
Neonatal necrotizing enterocolitis (NEC) is a devastating and unpredictable gastrointestinal disease with a high mortality rate in premature infants. Currently, no predictive or diagnostic biomarkers exist for NEC. Clinical intervention is reactive to the overt manifestations of disease resulting in high levels of morbidity and mortality. To better understand the molecular mechanisms that underpin NEC, we have undertaken a high resolution genome wide epigenomic analysis using solution phase hybridization and next generation DNA sequencing of bisulfite converted DNA. Our data reveal a broad and significant genomic hypermethylation in surgical NEC tissues compared to non-NEC controls. These changes were found to be far more pronounced in regions outside CpG islands and gene regulatory elements, which suggests that NEC-specific hypermethylation is not a non-specific global phenomenon. We identified a number of important biological pathways that are dysregulated in NEC and observed a clear association between NEC methylation changes and gene expression. Significantly, we found that the same patterns of global methylation identified in surgical NEC tissue are also detectable in stool samples from affected infants. To our knowledge, this is the first evidence of a methylomic signature that is both associated with NEC and detectable non-invasively. These findings point towards a new opportunity for the development of novel screening, diagnostic and phenotyping methods for NEC that could be deployed in the NICU for improved detection of this devastating disease.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
MG was supported by K08DK101608, R03DK111473, R01DK118568 and Pediatric Loan Repayment Program from the National Institutes of Health, March of Dimes Foundation Grant No. 5-FY17-79, and the Childrens Discovery Institute of Washington University in St. Louis. DP was supported by grants from the Pittsburgh Health Data Alliance (PHDA) and Magee-Womens Research Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
University of Pittsburgh Institutional Review Board (IRB) Protocols: PRO09110437, PRO14070508, PRO09110437, PRO14070508 Washington University in St. Louis Institutional Review Board (IRB) Protocols: 201706182
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Primary data are available from the authors on reasonable request.
